SYGNIS AG

euro adhoc: Sygnis Pharma AG
Fusion/Übernahme/Beteiligung
SYGNIS announces agreement on acquisition of Amnestix Inc., USA by partially using the authorized capital

-------------------------------------------------------------------------------- Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Unternehmen 08.06.2008 Heidelberg, June 8, 2008 - Today, after approval of the supervisory board, SYGNIS Pharma AG signed a contract according to which SYGNIS Pharma AG shall acquire all shares of Amnestix Inc., a privately-owned US biopharmaceutical company located at Burlingame, CA. With the acquisition of Amnestix Inc., SYGNIS extends its portfolio of compounds relating to the central nervous system (CNS) and secures IP-rights of compound-candidates for the treatment of CNS-disorders. In addition, SYGNIS gains access to a broad range of CNS projects within the Translational Genomics Research Institute in Phoenix, Arizona, a world-renowned research-institute in the field of neurogenomics. Amnestix was founded by scientists from Translational Genomics Research Institute in 2006 to develop novel therapeutics and molecular diagnostics technologies for improving cognition and memory. The founders of Amnestix Inc. have discovered a series of novel patentable genes and pathways that play a fundamental role in memory performance in humans. Amnestix´ Chief Executive Officer, Dr. Karoly Nikolich, will remain with Amnestix Inc. in this function. SYGNIS will pay approximately EUR4 million in cash and in SYGNIS-shares for all shares of Amnestix Inc. Therefore, the management and supervisory board of SYGNIS Pharma AG resolved today to issue 885.966 new common bearer SYGNIS-shares to the shareholders of Amnestix Inc. for the contribution in kind with the exclusion of the preemptive rights of SYGNIS shareholders. The current company´s capital stock will be increased by approximately 3,2%. For further information please contact: Dr. Franz-Werner Haas VP Operations / General Counsel Tel: +49 (0) 6221-454 812 Email: franz-werner.haas@sygnis.de Ende der Mitteilung euro adhoc -------------------------------------------------------------------------------- ots Originaltext: LION Bioscience AG Im Internet recherchierbar: http://www.presseportal.ch Rückfragehinweis: Dr. Franz-Werner Haas VP Operations / General Counsel Tel: +49 (0) 179 212 33 95 Email: franz-werner.haas@sygnis.de Branche: Biotechnologie ISIN: DE0005043509 WKN: 504350 Index: CDAX Börsen: Börse Frankfurt / Regulierter Markt/Prime Standard Börse Berlin / Freiverkehr Börse Hamburg / Freiverkehr Börse Stuttgart / Freiverkehr Börse Düsseldorf / Freiverkehr Börse Hannover / Freiverkehr Börse München / Freiverkehr

Das könnte Sie auch interessieren: